Differentiated product
Triptorelin pamoate
Ready-to-use depot injection · Advanced prostate cancer (palliative)
Product data
- Dosage form
- Ready-to-use depot injection
- Dosage-form group
- Injectable
- Therapeutic area
- Advanced prostate cancer (palliative)
- Reference product
- Powder for IM injection eq. 22.5 mg base per vial
- Status
- Under development
- Development stage
- 2 of 5 · Development
- Portfolio
- Differentiated product
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23